Jul 12, 2022 - Jul 13, 2022 / NTS GMT
Timothy Francis Lugo - William Blair & Company L.L.C., Research Division - Co-Group Head of Biopharma Equity Research
Good morning. I'm Tim Lugo, the head of biotech and pharma equity research here at William Blair. And it's my pleasure to welcome John Temperato, CEO of 9 Meters Biopharma. 9 Meters is a clinical-stage company, pioneering novel treatments for people with rare or debilitating digestive diseases.
And before we dig into our discussion this morning, I will say this morning, even though we're really recording in the afternoon, but that's a little bit of insider knowledge there, I should tell you that everyone needs to look at williamblair.com for all relevant disclosures.
And with that, it's my pleasure to welcome you, John. I know you recently had some data. And before we dig into the data, I think maybe we could start with just a brief overview of what 9 Meters is all about and what you're trying to tackle.
John Temperato - 9 Meters Biopharma, Inc. - President, CEO & Director
Sure. Well, first of all, thank you,
9 Meters Biopharma Inc at William Blair Biotech Focus Conference Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers